tenofovir alafenamide (Vemlidy)
Small molecule
Evidence outlook
Approved: Chronic Hepatitis B
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Chronic hepatitis B in adults and adolescents aged 12 years and older weighing at least 35 kg (Vemlidy 25 mg)
- Vemlidy is indicated for the treatment of chronic hepatitis B (CHB) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.1).
- Suppression of viral replication in chronic hepatitis B patients with evidence of hepatitis B virus replication (Vemlidy 25 mg)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01940341 NCT01940341 · Chronic Hepatitis B This was an adequately powered, randomized, double-blind, active-controlled trial of 425 participants. The primary endpoint—HBV DNA suppression below 29 IU/mL at Week 48—met the prespecified non-inferiority margin for TAF compared with TDF, supporting strong evidence for a comparable antiviral effect. Registry: NCT01940341 | 3 | Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL (Week 48) 2015-09-30 | Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL (Week 48): TAF 25 mg 94 Percentage of participants | TDF 300 mg 92.9 Percentage of participants | Reliable signal | link ↗ |
View 4 more trials
NCT01940471 NCT01940471 · Chronic Hepatitis B This was a randomized, double-blind, active-controlled phase 3 trial with 875 participants. The primary clinical endpoint, HBV DNA below 29 IU/mL at Week 48, met the prespecified non-inferiority margin for TAF compared with TDF, supporting a strong evidence grade. Registry: NCT01940471 | 3 | Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 2015-11-16 | Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 (Week 48): TAF 25 mg 63.9 percentage of participants | TDF 300 mg 66.8 percentage of participants | Reliable signal | link ↗ |
NCT02979613 NCT02979613 · Chronic Hepatitis B The study randomly assigned participants to double-blind TAF or active-control TDF, with 245 participants per group at enrollment. The primary virologic endpoint was met: TAF was non-inferior to TDF for maintaining HBV suppression, with a between-group difference of 0.0 percentage points and a 95% confidence interval of −1.9 to 2.0, within the prespecified 4% margin. Registry: NCT02979613 | 3 | Percentage of Participants With Hepatitis B Virus (HBV) DNA Levels ≥ 20 IU/mL at Week 48, as Determined by the Modified United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm 2018-09-10 | Percentage of Participants With Hepatitis B Virus (HBV) DNA Levels ≥ 20 IU/mL at Week 48, as Determined by the Modified United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm (Week 48): TAF 25 mg 0.4 percentage of participants | TDF 300 mg 0.4 percentage of participants | Reliable signal | link ↗ |
OAV NCT03180619 · Chronic Hepatitis B The study was nonrandomized, open-label, and single-arm, with all 124 participants switching to tenofovir alafenamide and no placebo or active comparator. Although the primary virologic response results were favorable, the absence of randomization and a comparator means the observed outcomes cannot reliably be attributed to the switch itself. Registry: NCT03180619 | 2 | Percentage of Participants Achieving Virologic Response (Plasma Hepatitis B Virus [HBV] Deoxyribonucleic Acid [DNA] < 20 IU/mL) at Week 24; Percentage of Participants Who Experienced Graded Treatment-Emergent Adverse Events (AEs) at Week 24; Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 24 2019-03-27 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
NCT02932150 NCT02932150 · Chronic Hepatitis B Registry: NCT02932150 | 2 | Incidence of Treatment-Emergent Serious Adverse Events (SAEs) at Week 24; Incidence of Treatment-Emergent Adverse Events (AEs) at Week 24; Percentage of participants with plasma HBV DNA < 20 IU/mL at Week 24; PK Parameter: AUCtau of TAF for participants from Cohort 2 Part A (Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 or 12) 2026-10-27 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (20)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (33)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (6)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Phase 4 (1)
What this study did
Studied as part of a combination product (131)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 3 (42)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (37)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (4)
What this study did
What this study did
What this study did
What this study did
Appears in other studies (5)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other HBV polymerase (reverse transcriptase) drugs
Entecavir (Baraclude), lamivudine (Epivir-HBV), Besifovir dipivoxil (Besivo), Tenofovir amibufenamide (Hengmu), Entecavir (Cavir). Compare all 6 HBV polymerase (reverse transcriptase) drugs
7 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Chronic Hepatitis B: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tenofovir Alafenamide (Vemlidy): this drug | Approved | Small molecule | HBV polymerase (reverse transcriptase) | Reliable signal | Featured results are non-efficacy only in this race | |
| Entecavir (Baraclude) | Approved | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| Hepatitis B Immune Globulin (HepaGam B) | Approved | Protein / enzyme therapeutic | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| Interferon Alfa-2b (Intron A) | Approved | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Lamivudine (Epivir-HBV) | ApprovedUS marketing discontinued | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| Peginterferon Alfa-2a (Pegasys) | Approved | — | Type I interferon receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Tenofovir Disoproxil Fumarate (Viread) | Approved | Small molecule | HIV reverse transcriptase (RT) | Reliable signal | NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants | |
| Besifovir Dipivoxil (Besivo) | Phase 3 | Small molecule | HBV polymerase (reverse transcriptase) | Partial signal | NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019). | |
| Hepatitis B Immune Globulin (I.V.-Hepabig) | Phase 3 | Polyclonal Antibody (human Hepatitis B Immunoglobulin) | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| Tenofovir Amibufenamide (Hengmu) | Phase 3 | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| TQA3605 | Phase 3 | — | HBV core protein | not yet graded | No reviewed efficacy summary in this indication | |
| TVAX-008 | Phase 3 | Vaccine | Hepatitis B virus antigens (HBsAg + HBcAg) | not yet graded | No reviewed efficacy summary in this indication | |
| AHB-171 | Phase 2 | RNA / oligonucleotide | HBV RNA | not yet graded | No reviewed efficacy summary in this indication | |
| Daplusiran / Tomligisiran | Phase 2 | RNA / oligonucleotide | HBV RNA (X and S transcripts) | not yet graded | No reviewed efficacy summary in this indication | |
| Envafolimab | Phase 2 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Hepalatide | Phase 2 | Peptide | NTCP | not yet graded | No reviewed efficacy summary in this indication | |
| Libevitug (HH-003) | Phase 2 | Monoclonal antibody | HBV/HDV large envelope protein (PreS1 domain) | not yet graded | No reviewed efficacy summary in this indication | |
| Metacavir | Phase 2 | Small molecule | HBV reverse transcriptase (nucleoside analog) | not yet graded | No reviewed efficacy summary in this indication | |
| REP 2139-Mg | Phase 2 | — | HBsAg release (nucleic acid polymer) | not yet graded | No reviewed efficacy summary in this indication | |
| T101 | Phase 2 | Biologic (subtype unspecified) | HBV core, polymerase and envelope antigens | not yet graded | No reviewed efficacy summary in this indication | |
| TQA3810 | Phase 2 | — | TLR8 | not yet graded | No reviewed efficacy summary in this indication | |
| CRMA-1001 | Phase 1/2 | Gene therapy / editing | HBV genome (cccDNA and integrated DNA) | not yet graded | No reviewed efficacy summary in this indication | |
| Hepadvax | Phase 1/2 | Vaccine | HBsAg (PreS) immunization | not yet graded | No reviewed efficacy summary in this indication | |
| Human Serum Albumin / Interferon Alpha2b Fusion Protein | Phase 1/2 | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| LW231 | Phase 1/2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| PA1010 | Phase 1/2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| TQA3038 | Phase 1/2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| ACT201 | Phase 1 | RNA / oligonucleotide | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| CB06-036 | Phase 1 | — | TLR8 | not yet graded | No reviewed efficacy summary in this indication | |
| DA-2803 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Entecavir (Cavir) | Phase 1(overall) | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| HECN30227 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| SA1211 | Phase 1 | RNA / oligonucleotide | Hepatitis B virus RNA (dual-target siRNA) | not yet graded | No reviewed efficacy summary in this indication | |
| TVAX-028 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Adefovir Dipivoxil (Hepsera) | Discontinued | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| Obeticholic Acid (Ocaliva) | Discontinued | — | FXR | not yet graded | No reviewed efficacy summary in this indication | |
| Pamrevlumab | Discontinued | Monoclonal antibody | CTGF | not yet graded | No reviewed efficacy summary in this indication | |
| Telbivudine (Tyzeka) | Discontinued | — | HBV polymerase (reverse transcriptase) | Partial signal | NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed |
Upcoming events
(17 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow tenofovir alafenamide (Vemlidy) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.